Additionally, the recently published SUMMIT trial44 demonstrated that GLP-1 RA use significantly reduced a composite of decompensated HF and CV death in patients with obesity and HF with preserved ejection fraction. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.